Mitigating blood loss and avoiding the need for a blood transfusion are among primary concerns regarding joint replacement surgery. The study conducted by researchers at the Hospital for Special Surgery in New York reviewed the records of 4,449 patients who had a hip or knee replacement over a six month period. There were 720 patients who received TXA topically, 636 received it intravenously and 3,093 patients received no TXA. Approximately 22 percent of patients who were not given TXA received a blood transfusion. Less than 10 percent of patients who were treated with TXA were given a blood transfusion. There was no significant difference in blood clots between patients who received TXA topically and those who given the drug intravenously — the researchers suggest this confirms the drug’s safety.
The study was presented Tuesday in Orlando, Fla., at the annual meeting of the American Academy of Orthopaedic Surgeons.
More articles on quality:
Parents are untapped resource for the reduction of medical errors, study finds
Are hand dryers doing more harm than good? 5 things to know
Your secret value-based weapon for improving patient engagement and access to care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
